Chief executive Chris Viehbacher said on Biogen's results call that a plan to extend the use of the subcutaneous injector into the induction phase of treatment could be a "game changer." ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version ... even at home using a self-injector. Alteogen will use its ...

Its weekly subcutaneous GIP ... Additionally, an auto-injector, in my view, is only a minor enhancement (arguably negligible) compared to prefilled injection pens. Either Lilly or Novo could ...